Triple-negative breast cancer: future prospects in diagnosis and management

Elsamany, Shereef; Abdullah, Sakher
February 2014
Medical Oncology;Feb2014, Vol. 31 Issue 2, p1
Academic Journal
No abstract available.


Related Articles

  • ADVANCES IN THE MANAGEMENT OF METASTATIC HER2-POSITIVE AND TRIPLE-NEGATIVE BREAST CANCER. Suipher, Jeffrey; Dent, Susan // Oncology Exchange;Feb2014, Vol. 13 Issue 1, p26 

    The article presents several abstracts and commentaries related to the management of metastatic HER2-positive and triple-negative breast cancer in patients in Canada.

  • Improved systemic therapy goal for triple-negative breast-cancer. Shafer, Emily // Hem/Onc Today;4/25/2011, Vol. 12 Issue 8, p16 

    The article discusses treatment options for triple-negative breast cancer.

  • Tips and tricks in triple-negative breast cancer: how to manage patients in real-life practice? Piccart, M.; Viale, G.; Ellis, P.; Abramowicz, M.; Carey, L. // Ecancermedicalscience;2011, Vol. 5, p1 

    Information about several topics discussed at the International Breast Cancer Conference held on January 29, 2011 to deal with triple-negative breast cancer (TNBC)is presented. Topics included the definition of TNBC, subtypes, patient treatment and family diagnosis, based on live patient with...

  • Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Fostira, Florentia; Tsitlaidou, Marianthi; Papadimitriou, Christos; Pertesi, Maroulio; Timotheadou, Eleni; Stavropoulou, Alexandra; Glentis, Stavros; Bournakis, Evangelos; Bobos, Mattheos; Pectasides, Dimitrios; Papakostas, Pavlos; Pentheroudakis, George; Gogas, Helen; Skarlos, Pantelis; Samantas, Epaminontas; Bafaloukos, Dimitrios; Kosmidis, Paris; Koutras, Angelos; Yannoukakos, Drakoulis; Konstantopoulou, Irene // Breast Cancer Research & Treatment;Oct2012, Vol. 134 Issue 1, p353 

    In spite the close association of the triple-negative breast cancer immunophenotype with hereditary breast cancers and the BRCA1 pathway, there is a lack of population studies that determine the frequency of BRCA1 mutations among triple-negative breast cancer patients. To address this, we have...

  • Triple-negative breast cancers: an updated review on treatment options. Reddy, K. B. // Current Oncology;Aug2011, Vol. 18 Issue 4, pe173 

    Morphologic features of tumour cells have long been validated for the clinical classification of breast cancers and are regularly used as a "gold standard" to ascertain prognostic outcome in patients. Identification of molecular markers such as expression of the receptors for estrogen (ER) and...

  • Race, Ethnicity, and the Diagnosis of Breast Cancer. Daly, Bobby; Olopade, Olufunmilayo I. // JAMA: Journal of the American Medical Association;1/13/2015, Vol. 313 Issue 2, p141 

    The author discusses various topics associated with race, ethnicity, and the diagnosis of breast cancer. Topics discussed include an article within the issue of the periodical about differences in the likelihood of diagnosis with stage I breast cancer and risk of death among ethnic/racial groups...

  • Triple-Negative Breast Cancer. Foulkes, William D.; Smith, Ian E.; Reis-Filho, Jorge S. // New England Journal of Medicine;11/11/2010, Vol. 363 Issue 20, p1938 

    The article discusses the occurrence of triple-negative breast cancer in women and the increase in its recognition by geneticists, pathologists, and oncologists in the U.S. in 2010. Basal-like breast cancer is related to triple-negative breast cancer. Triple-negative breast cancers are also...

  • Effect of statins on breast cancer recurrence and mortality: a review. Van Wyhe, Renae D.; Rahal, Omar M.; Woodward, Wendy A. // Breast Cancer: Targets & Therapy;Dec2017, Vol. 9, p559 

    Statins, or 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors, are medications that have been used for decades to lower cholesterol and to prevent or treat cardiovascular diseases. Since their approval by the US Food and Drug Administration in the 1980s, other potential uses for statins...

  • Triple-Negative Breast Cancer Therapy Target? Breindl, Anette // BioWorld Today;8/14/2013, Vol. 24 Issue 155, p1 

    The article offers information on basal-like triple-negative breast cancer, a common subtype of triple-negative breast cancer, identified by scientists from Harvard University.

  • Prognostic factors for survival of women with unstable spinal bone metastases from breast cancer. Foerster, Robert; Bruckner, Thomas; Bostel, Tilman; Schlampp, Ingmar; Debus, Juergen; Rief, Harald // Radiation Oncology;2015, Vol. 10 Issue 1, p1 

    Background: Bone metastases are an important clinical issue in women with breast cancer. Particularly, unstable spinal bone metastases (SBM) are a major cause of severe morbidity and reduced quality of life (QoL) due tofrequent immobilization. Radiotherapy (RT) is the major treatment modality...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics